Education
About Us
Working with TipRanks
Follow Us
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
Earnings Data
Report Date
Nov 11, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
0.36Last Year’s EPS
0.12Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
TransMedics demonstrated strong financial performance in Q2 2025, with record revenue growth and a healthy cash position. The company is making progress on key clinical programs and has raised its full-year guidance. However, it faces ongoing challenges in the lung perfusion market and anticipates some seasonal impacts in Q3. Overall, the company's strengths and positive developments outweigh the challenges.Company Guidance -
Q3 2025
Record Revenue Growth
TransMedics reported total revenue of $157.4 million for Q2 2025, marking a 38% year-over-year growth and a 10% sequential increase. This growth was driven by higher utilization across all organ segments.
Strong Operating Profit
The company achieved an operating profit of $36.6 million, which is more than 23% of total revenue, up from $27.4 million or 19% of total revenue in Q1 2025.
Healthy Cash Position
TransMedics reported strong cash generation, ending Q2 with over $400 million in cash, an increase of approximately $90 million from the previous quarter.
OCS Lung and Heart IDE Approvals
The company received FDA conditional approval for the OCS Lung IDE in July and expects to launch both the OCS Lung and Heart clinical programs before year-end.
Increased Full Year Revenue Guidance
TransMedics raised its full-year 2025 revenue guidance to between $585 million and $605 million, representing approximately 35% growth over full year 2024 at the midpoint.
TMDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TMDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jul 30, 2025 | $107.70 | $118.97 | +10.46% |
May 08, 2025 | $93.20 | $111.50 | +19.64% |
Feb 27, 2025 | $72.12 | $76.32 | +5.82% |
Oct 28, 2024 | $126.24 | $88.50 | -29.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does TransMedics Group Inc (TMDX) report earnings?
TransMedics Group Inc (TMDX) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).
What is TransMedics Group Inc (TMDX) earnings time?
TransMedics Group Inc (TMDX) earnings time is at Nov 11, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TMDX EPS forecast?
TMDX EPS forecast for the fiscal quarter 2025 (Q3) is 0.36.